![]() |
市場調查報告書
商品編碼
2133420
肱二頭肌腱固定術市場規模、佔有率和趨勢分析 |全球| 2026–2032 | 包括縫合線、錨釘和螺絲Biceps Tenodesis Market Size, Share and Trends Analysis | Global | 2026-2032 | Includes: Suture Anchors and Screws |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2025年全球肱二頭肌腱固定術市場規模略高於1.35億美元。預計該市場將以4.9%的複合年成長率成長,到2032年達到略低於1.9億美元。
本報告重點在於用於肱二頭肌腱固定術的縫合錨釘和肌腱固定螺絲。報告根據截至2022年的歷史數據和截至2032年的預測數據,對各公司的銷售量、手術例數、平均售價、市場規模、成長率和市場佔有率進行了定量分析。
兩大臨床趨勢正在推動市場成長。首先,隨著越來越多的證據支持肌腱切斷術,一些肱二頭肌腱切除手術手術正逐漸轉向肌腱固定術。這主要是因為切除手術會導致較高的外觀畸形發生率,包括「大力水手徵」。其次,從SLAP損傷修復術到肱二頭肌肌腱固定術的廣泛轉變正在逐步增加手術量。這是因為外科醫師越來越意識到,肌腱固定術的併發症率更低,且患者恢復到傷前活動量的比例更高。
由於手術時間短、復健較簡單,肌腱切開術仍然是老年患者和活動量低的患者的可行選擇,這限制了肌腱固定術全面普及的進程。此外,手術向門診手術中心(ASC)的轉移也對器械價格造成了下行壓力,儘管手術需求增加,但兩種產品類型的平均售價(ASP)均未出現上漲。
市場概覽
全球肱二頭肌腱固定術市場是肩關節修復手術中的一個細分領域,專注於將肱二頭肌長頭肌腱固定於肱骨。雖然與規模大規模的整形外科市場相比,該市場整體規模小規模,但由於臨床證據支持肌腱固定術的成功,以及隨著肌腱切除手術和SLAP損傷修復術的逐步減少,手術數量不斷增加,該市場正穩步成長。縫合錨釘和肌腱固定螺絲均可作為主要的固定裝置,產品研發的目標是實現全關節鏡手術、提高生物相容性並增強手術技術的靈活性。
肌腱固定術和肌腱切斷術之間的比較是該市場最直接的商業性促進因素。一項於2025年進行的多中心試驗證實,兩種手術均能取得相似的功能性結果,但結果顯示,接受肌腱切斷術的患者出現外觀畸形的發生率顯著高於接受肌腱固定術的患者。這種差異促使部分患者轉向使用肌腱固定裝置,尤其是在那些優先考慮保持旋後力量和外觀的年輕活躍患者中。另一方面,由於切除手術切斷術手術時間較短且無需植入植入,因此對於老年患者和運動量較低的患者而言,它仍然是一種合適且常用的選擇,這也限制了肌腱固定術的普及速度。
從SLAP修復術轉向肱二頭肌腱固定術也是推動該市場手術量成長的原因之一。 2025年的臨床數據顯示,肱二頭肌腱固定術後的患者預後優於SLAP修復術,併發症率更低,恢復到傷前活動量的比例更高。隨著肱二頭肌腱固定術逐漸被公認為肱二頭肌長頭損傷的標準治療方法,手術中使用的縫合錨釘和阻斷式骨釘在肩關節手術市場中的佔有率也越來越大。
目前,相當一部分肱二頭肌腱修復手術在門診手術中心進行。這些機構優先考慮高效經濟的關節鏡手術,其財務結構也比傳統醫院更為精簡。這種轉變抑制了醫療設備價格的上漲,縫線錨釘和肌腱固定成本績效的平均售價均有所下降。為了因應這一環境,產品研發的重點在於開發經濟高效的材料,例如生物複合材料和聚醚醚酮(PEEK),這些材料既能滿足臨床標準,又不會造成高昂的成本負擔,同時還能與關節鏡手術相容,並提高手術效率。
從肌腱切除手術到肌腱固定的過渡
2025年的臨床證據表明,對於活躍患者和注重外觀的患者,在肱二頭肌腱修復方面,肌腱切除手術仍然優於肌腱切斷術。一項2025年的多中心試驗證實,雖然兩種手術的功能結果相當,但接受肌腱切斷術的患者出現「切除手術徵」(Popeye's sign)的發生率顯著高於接受肌腱固定術的患者。這種外觀差異是促使部分肱二頭肌腱修復手術轉向肌腱固定裝置的主要因素。由於手術時間短、骨損傷小、恢復過程簡單,肌腱切除手術仍是老年患者和低活動量患者的可行選擇。然而,對於注重旋後力量和外觀的患者,肌腱固定術正日益受到青睞。這種轉變是推動市場上此類手術數量逐步成長的主要因素。
肌腱固定術與SLAP修復術
從SLAP修復術到肱二頭肌腱固定術的廣泛臨床轉變正在推動肱二頭肌腱固定術市場的成長。雖然SLAP修復術曾是治療肱二頭肌相關肩痛的標準手術方法,但臨床經驗和長期療效數據正促使外科醫師逐漸傾向於採用腱固定術。預計到2025年,臨床數據顯示,與SLAP修復術相比,肱二頭肌腱固定術併發症發生率更低、再次手術率更低,且患者恢復到傷前活動量的速度更快。隨著這一趨勢在全球臨床實踐中日益確立,肱二頭肌腱固定術在肩關節修復中的佔有率不斷擴大,從而帶動了對該適應症所需的縫合錨釘和阻斷式骨釘的需求。
門診護理和日間手術中心的價格壓力
目前,相當一部分的肱二頭肌腱修復手術是在門診手術中心(ASC)進行。與傳統醫院相比,門診手術中心的財務狀況更為艱難,為了維持盈利,它們優先考慮經濟實惠的關節鏡手術。這種手術轉移到門診手術中心的趨勢,持續對醫療設備價格構成下行壓力,縫合錨釘和肌腱固定螺絲的平均售價(ASP)成長均受到抑制。門診手術中心的業者經常就耗材價格進行激烈的談判,並可能為了控制成本而採用低成本產品作為標準。這種商業環境限制了製造商將產品創新帶來的價格上漲轉嫁給消費者,導致儘管手術數量增加,但整體市場價值成長卻放緩。
肌腱截肢切除手術是一種更簡單的外科手術替代方案
肱二頭肌腱固定術比腱切開術更複雜、更耗時,在某些患者群體中,腱切開術仍然是廣泛接受的替代方案。腱切開術無需植入植入,從而最大限度地減少了骨創傷,縮短了手術時間,並簡化了術後復原。對於老年患者或體力活動程度較低的患者,由於維持旋後力量或避免外觀畸形並非至關重要,腱切開術通常是首選方案。由於這種更簡單的替代方案仍然有效且在臨床上被廣泛接受,因此從肱二頭肌修復術完全過渡到腱切開術的趨勢有限,並且該適應症對縫合錨釘和腱切開螺釘的總需求量也存在自然的上限。
The global biceps tenodesis market was valued at just over $135 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of 4.9%, reaching just under $190 million by 2032.
This report covers suture anchors and tenodesis screws used in biceps tenodesis procedures. It quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
Two clinical trends are supporting market growth. First, growing evidence favoring tenodesis over tenotomy is driving a partial conversion of biceps tendon repairs toward tenodesis devices, primarily because tenotomy carries a higher rate of cosmetic deformity, including the Popeye sign. Second, the broader shift from SLAP repair to biceps tenodesis is adding incremental procedure volume, as surgeons increasingly find that tenodesis delivers lower complication rates and higher rates of return to preinjury activity.
Tenotomy remains a relevant alternative for older and lower-demand patients due to its shorter operative time and simplified rehabilitation, which limits the pace of full conversion. The migration of procedures to ambulatory surgery centers (ASCs) is also placing downward pressure on device pricing, constraining ASP growth across both product categories despite rising procedural demand.
Market Overview
The global biceps tenodesis market is a focused, specialized segment within shoulder repair, centered on the fixation of the long head of the biceps tendon to the humerus. While total market value is modest relative to larger orthopedic categories, the market is growing steadily as clinical evidence supports tenodesis outcomes and procedure volumes increase through gradual conversion from tenotomy and SLAP repair. Both suture anchors and tenodesis screws serve as core fixation devices, with product development oriented toward fully arthroscopic delivery, improved biocompatibility, and expanded procedural versatility.
The comparison between tenodesis and tenotomy is the most direct commercial driver in this market. A 2025 multicenter trial confirmed that both procedures achieve comparable functional outcomes, but patients undergoing tenotomy experience a significantly higher incidence of cosmetic deformity compared to those receiving tenodesis. This difference is driving a partial conversion toward tenodesis devices, particularly among younger and more active patients who prioritize preservation of supination strength and cosmetic appearance. Tenotomy remains a suitable and frequently chosen option for older or lower-demand patients due to its shorter operative time and the absence of fixation hardware requirements, which limits the pace of conversion to tenodesis procedures.
The shift from SLAP repair to biceps tenodesis is also contributing to procedure volume growth within this market. Clinical data in 2025 indicates more favorable patient outcomes following tenodesis compared to SLAP repair, with lower complication rates and higher return to preinjury activity levels. As biceps tenodesis is increasingly recognized as the preferred standard for managing long head of biceps pathology, the suture anchors and interference screws used in these procedures are capturing a larger share of the broader surgical shoulder market.
A substantial portion of biceps tendon repairs now take place within ambulatory surgery centers. These facilities prioritize efficient and economical arthroscopic techniques and operate with leaner financial profiles than traditional hospital settings. This shift has placed downward pressure on device pricing, limiting ASP growth across both suture anchor and tenodesis screw categories. Product development in response to this environment has focused on arthroscopic compatibility, procedural efficiency, and value-oriented materials such as biocomposite and PEEK that meet clinical standards without premium pricing burdens.
Market Drivers
Conversion from Tenotomy to Tenodesis
Clinical evidence in 2025 continues to favor tenodesis over tenotomy for biceps tendon repair in active and cosmetically conscious patient populations. A 2025 multicenter trial confirmed that while both procedures achieve comparable functional outcomes, patients undergoing tenotomy experience a meaningfully higher incidence of the Popeye sign compared to those receiving tenodesis. This cosmetic difference is a key factor driving partial conversion of biceps repairs toward tenodesis devices. Tenotomy remains a reasonable choice for older or lower-demand patients given its shorter operative time, reduced bone trauma, and simplified recovery, but for patients who place value on supination strength and physical appearance, tenodesis is the increasingly preferred approach. This conversion trend is the primary source of incremental procedure volume growth in the market.
Tenodesis versus SLAP Repair
The broader clinical migration from SLAP repair to biceps tenodesis is adding procedural volume to the biceps tenodesis market. SLAP repair was previously the surgical standard for managing biceps-related shoulder pain, but clinical experience and longitudinal outcome data have shifted surgeon preference toward tenodesis. Clinical data in 2025 indicates that biceps tenodesis offers lower complication rates, fewer reoperations, and higher rates of return to preinjury activity levels compared to SLAP repair. As this preference becomes more firmly embedded across clinical settings globally, biceps tenodesis is capturing a larger share of shoulder repair procedures, creating demand for the suture anchors and interference screws central to this indication.
Market Limiters
Outpatient Settings and ASC Pricing Pressure
A substantial number of biceps tendon repairs now occur within ambulatory surgery centers, which operate with leaner financial profiles than traditional hospital settings and prioritize economical arthroscopic techniques to maintain profitability. The migration of procedures to these facilities has exerted sustained downward pressure on device pricing, constraining ASP growth across both suture anchor and tenodesis screw categories. ASC administrators frequently negotiate aggressively on consumable pricing and may standardize on lower-cost product options to control costs. This operating environment limits the ability of manufacturers to pass on price increases tied to product innovation, moderating overall market value growth despite a rising procedure count.
Tenotomy as a Simpler Surgical Alternative
Biceps tenodesis is a more complex and time-consuming procedure than tenotomy, and tenotomy remains a widely accepted alternative for specific patient demographics. Tenotomy minimizes bone trauma by eliminating the need for fixation hardware, reduces operative time, and simplifies post-operative rehabilitation. For older or lower-demand patients where preservation of supination strength and avoidance of cosmetic deformity are less critical priorities, tenotomy is frequently the preferred choice. The continued viability and clinical acceptance of this simpler alternative limits the full conversion of biceps repairs to tenodesis procedures, placing a natural ceiling on total suture anchor and tenodesis screw demand within this indication.
Market Coverage and Data Scope
Markets Covered and Segmentation
Competitive Analysis
Arthrex continued to lead the biceps tenodesis market in 2025, maintaining a dominant position through consistent product development across both suture anchor and interference screw categories. The company offers the SwiveLock Tenodesis Implant line, designed for both proximal and distal procedures and available in various eyelet configurations to support diverse surgical techniques. The FiberTak Biceps Implant System provides a high-strength, all-suture anchor solution designed to minimize bone removal during repair. Arthrex also offers the Tenodesis Screw in BioComposite and PEEK materials, which remains a standard for secure tendon-to-bone fixation in the humerus and addresses the full spectrum of clinical tenodesis approaches.
Smith and Nephew held the second position in the biceps tenodesis market in 2025. The company sells the BICEPTOR Tenodesis System, which supports fully arthroscopic surgeries using BIOSURE PK Interference Screws. For suture anchor applications in biceps tenodesis, Smith and Nephew offers the Q-FIX all-suture product, giving the company coverage across both core device categories in the market.
DePuy Synthes remained the third leading competitor in 2025. The company offers the MILAGRO Advance Interference Screw in BIOCRYL RAPIDE biocomposite and PEEK materials. The HEALIX product line includes suture anchors across PEEK, biocomposite, and metal material types. In early 2025, DePuy Synthes expanded this portfolio with the TIGHT-N anchor, an inlay tendon docking device designed to protect the tendon from laceration while delivering high-strength sub-cortical fixation.
Technology and Practice Trends
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
The Global Biceps Tenodesis Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, prioritize product development investments, and plan for growth across all major global regions.